Skip to main content
29th Annual Scientific Assembly Main banner
Back
Evaluation

Scientific Assembly

Track Session

Session: Session 305

Here’s What’s New (and Not) with Treating Sickle Cell Patients in the ED: A Rapid-fire Review

Monday, April 24, 2023
11:15 AM – 11:35 AM CST
Location: Salon FGH-3rd Floor
CE: 0.25 Credits
Hematology and Oncology Recorded Session
Disclosure(s):
Joseph S. Colla, MD: No financial relationships to disclose
This talk is a well-timed, high-level but extremely informative presentation regarding the evaluation and treatment of patients with sickle cell disease (SCD) presenting to the emergency department (ED). Dr. Colla will first review the up-to-date, evidence-based and expert consensus recommendations from the National Heart Blood and Lung Institute (NHBLI) and the American Society of Hematology (ASH) regarding evaluation and treatment of SCD patients in the ED. He will then briefly highlight some of the latest developments and trends with regard to the management of sickle cell disease in the acute care setting. Finally, he will review the efficacy, scope, and in some instances, controversies surrounding recent FDA approved therapies and other experimental therapies for sickle cell disease.

Learning Objectives:

  • Review the up-to-date, evidence-based and expert consensus recommendations from the NHBLI and ASH regarding the management of sickle cell patients presenting to the emergency department
  • Highlight some of the latest developments and trends with regard to the management of sickle cell disease in the acute care setting
  • Briefly review the efficacy, scope, and in some instances, controversies surrounding recent FDA approved therapies and other experimental therapies for sickle cell disease